Fusion Antibodies Shares Plunge 35% on H1 FY27 Revenue Shortfall at AGM

The Quick Take

• Fusion Antibodies disclosed lower-than-expected H1 FY27 revenues at its AGM, triggering a 35%+ share price plunge.
• The clinical CRO cited execution challenges as revenues for the period ending September 30, 2026 missed targets.
• Management addressed shareholders directly at the AGM, signaling transparency but no immediate revenue recovery plan.

Fusion Antibodies operates in the contract research organization sector, providing antibody engineering and discovery services to biopharmaceutical clients. A mid-year revenue shortfall at a specialized CRO signals project pipeline delays or client spending pullbacks — patterns increasingly visible across smaller biotech service providers in 2026 as drug development budgets tighten amid rising capital costs.

A 35% single-session decline in a small-cap CRO signals severe market distrust of management guidance after missing revenue targets. Peer CROs — Evotec, Ergomed, and similar micro-cap service firms — face risk-off sentiment as investors apply a sector discount. Biotech service budgets from major pharma remain intact at tier-one operators, but smaller specialized CROs face client concentration risk and limited pricing power that amplifies revenue misses into disproportionate stock moves.

Watch for Fusion Antibodies Q2 FY27 trading update to determine whether the revenue shortfall is cyclical or structural. Key macro variables include pharma R&D spending guidance from major clients for calendar 2027 and the trajectory of small-cap biotech funding in the UK. A rights issue or strategic review announcement within 90 days would confirm the market's worst-case interpretation of the AGM disclosures.

Synthesized from 1 source.